Enlivex Therapeutics Competitors

Rigel Pharmaceuticals (NASDAQ:RIGL) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares Rigel Pharmaceuticals and Enlivex Therapeutics' revenue, earnings per share and valuation.

Enlivex Therapeutics has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rigel Pharmaceuticals and Enlivex Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 2.4% of Enlivex Therapeutics shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Rigel Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Rigel Pharmaceuticals and Enlivex Therapeutics, as provided by MarketBeat.

Rigel Pharmaceuticals currently has a consensus target price of $8.3333, suggesting a potential upside of 134.74%. Enlivex Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 242.68%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Rigel Pharmaceuticals.

Summary

Rigel Pharmaceuticals beats Enlivex Therapeutics on 7 of the 13 factors compared between the two stocks.

Enlivex Therapeutics (NASDAQ:ENLV) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Risk and Volatility

Enlivex Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

2.4% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are owned by institutional investors. 5.0% of Albireo Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Enlivex Therapeutics and Albireo Pharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Enlivex Therapeutics and Albireo Pharma, as reported by MarketBeat.com.

Enlivex Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 242.68%. Albireo Pharma has a consensus price target of $72.00, suggesting a potential upside of 128.50%. Given Enlivex Therapeutics' higher possible upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Albireo Pharma.

Earnings & Valuation

This table compares Enlivex Therapeutics and Albireo Pharma's top-line revenue, earnings per share and valuation.

Enlivex Therapeutics has higher earnings, but lower revenue than Albireo Pharma. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Albireo Pharma, indicating that it is currently the more affordable of the two stocks.

Enlivex Therapeutics (NASDAQ:ENLV) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Enlivex Therapeutics and AnaptysBio, as reported by MarketBeat.

Enlivex Therapeutics currently has a consensus price target of $33.00, indicating a potential upside of 242.68%. AnaptysBio has a consensus price target of $30.2857, indicating a potential upside of 38.23%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than AnaptysBio.

Earnings & Valuation

This table compares Enlivex Therapeutics and AnaptysBio's gross revenue, earnings per share (EPS) and valuation.

Enlivex Therapeutics has higher earnings, but lower revenue than AnaptysBio. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Enlivex Therapeutics and AnaptysBio's net margins, return on equity and return on assets.

Volatility and Risk

Enlivex Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Insider & Institutional Ownership

2.4% of Enlivex Therapeutics shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IDEAYA Biosciences (NASDAQ:IDYA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Profitability

This table compares IDEAYA Biosciences and Enlivex Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

IDEAYA Biosciences has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares IDEAYA Biosciences and Enlivex Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for IDEAYA Biosciences and Enlivex Therapeutics, as reported by MarketBeat.com.

IDEAYA Biosciences presently has a consensus price target of $31.4444, suggesting a potential upside of 69.42%. Enlivex Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 242.68%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than IDEAYA Biosciences.

Insider & Institutional Ownership

62.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 2.4% of Enlivex Therapeutics shares are held by institutional investors. 20.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences beats Enlivex Therapeutics on 7 of the 10 factors compared between the two stocks.

Enlivex Therapeutics (NASDAQ:ENLV) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Enlivex Therapeutics and Clovis Oncology, as provided by MarketBeat.

Enlivex Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 242.68%. Clovis Oncology has a consensus target price of $7.00, suggesting a potential upside of 23.46%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Clovis Oncology.

Valuation & Earnings

This table compares Enlivex Therapeutics and Clovis Oncology's gross revenue, earnings per share and valuation.

Enlivex Therapeutics has higher earnings, but lower revenue than Clovis Oncology. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Enlivex Therapeutics and Clovis Oncology's net margins, return on equity and return on assets.

Institutional & Insider Ownership

2.4% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Enlivex Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

SIGA Technologies (NASDAQ:SIGA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Risk and Volatility

SIGA Technologies has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Profitability

This table compares SIGA Technologies and Enlivex Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

29.3% of SIGA Technologies shares are held by institutional investors. Comparatively, 2.4% of Enlivex Therapeutics shares are held by institutional investors. 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for SIGA Technologies and Enlivex Therapeutics, as provided by MarketBeat.

Enlivex Therapeutics has a consensus target price of $33.00, indicating a potential upside of 242.68%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than SIGA Technologies.

Earnings and Valuation

This table compares SIGA Technologies and Enlivex Therapeutics' top-line revenue, earnings per share and valuation.

SIGA Technologies has higher revenue and earnings than Enlivex Therapeutics.

Summary

SIGA Technologies beats Enlivex Therapeutics on 8 of the 11 factors compared between the two stocks.